Literature DB >> 10647869

Drugs toxic to the bone marrow that target the stromal cells.

I Guest1, J Uetrecht.   

Abstract

Drugs that cause toxicity to the bone marrow are a heterogeneous group of compounds that act by various mechanisms. The etiology of this pathology is poorly understood but the highly proliferative nature of the hematopoietic cells is assumed to make the bone marrow more sensitive to toxicity. Recent evidence suggests that drugs can also affect specific aspects of stromal cells and the extracellular matrix that they establish. The data support the view that characteristics other than a high proliferation rate could confer susceptibility of the bone marrow to the toxic effects of drugs. This article discusses those drugs that have been shown to have direct effects on the bone marrow stromal cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647869     DOI: 10.1016/s0162-3109(99)00168-x

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  7 in total

Review 1.  Hierarchy of breast cancer cells: key to reverse dormancy for therapeutic intervention.

Authors:  Sarah A Bliss; Steven J Greco; Pranela Rameshwar
Journal:  Stem Cells Transl Med       Date:  2014-05-15       Impact factor: 6.940

2.  Human Wharton's jelly stem cells, its conditioned medium and cell-free lysate inhibit the growth of human lymphoma cells.

Authors:  Hao Daniel Lin; Chui Yee Fong; Arijit Biswas; Mahesh Choolani; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2014-08       Impact factor: 5.739

3.  Endothelial progenitors encapsulated in bioartificial niches are insulated from systemic cytotoxicity and are angiogenesis competent.

Authors:  B B Ratliff; T Ghaly; P Brudnicki; K Yasuda; M Rajdev; M Bank; J Mares; A K Hatzopoulos; M S Goligorsky
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-21

4.  Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair.

Authors:  Kaoru Yasuda; Hyeong-Cheon Park; Brian Ratliff; Francesco Addabbo; Antonis K Hatzopoulos; Praveen Chander; Michael S Goligorsky
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

5.  Bone marrow osteoblast vulnerability to chemotherapy.

Authors:  Marieta Gencheva; Ian Hare; Susan Kurian; Jim Fortney; Debbie Piktel; Robert Wysolmerski; Laura F Gibson
Journal:  Eur J Haematol       Date:  2013-05-03       Impact factor: 2.997

6.  Bone marrow osteoblast damage by chemotherapeutic agents.

Authors:  Stephanie L Rellick; Heather O'Leary; Debbie Piktel; Cheryl Walton; James E Fortney; Stephen M Akers; Karen H Martin; James Denvir; Goran Boskovic; Donald A Primerano; Jeffrey Vos; Nathanael Bailey; Marieta Gencheva; Laura F Gibson
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

7.  Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ.

Authors:  Tapasi Rana; Anwesa Chakrabarti; Michael Freeman; Swati Biswas
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.